TY - CHAP
T1 - Blood-brain barrier biomarkers
AU - Zapata-Acevedo, Juan F.
AU - Mantilla-Galindo, Alejandra
AU - Vargas-Sánchez, Karina
AU - González-Reyes, Rodrigo E.
N1 - Publisher Copyright:
© 2024
PY - 2024/4/22
Y1 - 2024/4/22
N2 - The blood-brain barrier (BBB) is a dynamic interface that regulates the exchange of molecules and cells between the brain parenchyma and the peripheral blood. The BBB is mainly composed of endothelial cells, astrocytes and pericytes. The integrity of this structure is essential for maintaining brain and spinal cord homeostasis and protection from injury or disease. However, in various neurological disorders, such as traumatic brain injury, Alzheimer's disease, and multiple sclerosis, the BBB can become compromised thus allowing passage of molecules and cells in and out of the central nervous system parenchyma. These agents, however, can serve as biomarkers of BBB permeability and neuronal damage, and provide valuable information for diagnosis, prognosis and treatment. Herein, we provide an overview of the BBB and changes due to aging, and summarize current knowledge on biomarkers of BBB disruption and neurodegeneration, including permeability, cellular, molecular and imaging biomarkers. We also discuss the challenges and opportunities for developing a biomarker toolkit that can reliably assess the BBB in physiologic and pathophysiologic states.
AB - The blood-brain barrier (BBB) is a dynamic interface that regulates the exchange of molecules and cells between the brain parenchyma and the peripheral blood. The BBB is mainly composed of endothelial cells, astrocytes and pericytes. The integrity of this structure is essential for maintaining brain and spinal cord homeostasis and protection from injury or disease. However, in various neurological disorders, such as traumatic brain injury, Alzheimer's disease, and multiple sclerosis, the BBB can become compromised thus allowing passage of molecules and cells in and out of the central nervous system parenchyma. These agents, however, can serve as biomarkers of BBB permeability and neuronal damage, and provide valuable information for diagnosis, prognosis and treatment. Herein, we provide an overview of the BBB and changes due to aging, and summarize current knowledge on biomarkers of BBB disruption and neurodegeneration, including permeability, cellular, molecular and imaging biomarkers. We also discuss the challenges and opportunities for developing a biomarker toolkit that can reliably assess the BBB in physiologic and pathophysiologic states.
UR - http://www.scopus.com/inward/record.url?scp=85190999766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85190999766&partnerID=8YFLogxK
U2 - 10.1016/bs.acc.2024.04.004
DO - 10.1016/bs.acc.2024.04.004
M3 - Chapter
AN - SCOPUS:85190999766
T3 - Advances in Clinical Chemistry
BT - Advances in Clinical Chemistry
PB - Academic Press Inc.
ER -